Advertisement
Screener

VAXCYTE, INC. (PCVX) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3

2.8 / 5 stars · 68/120 Roast Me

VAXCYTE, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3

VAXCYTE, INC. (PCVX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.

Financial Statements › Notes

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 · last filed 2026-02-24

  • VAXCYTE, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into level 3 for the quarter ending 2024-12-31 was $0.00.
  • VAXCYTE, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into level 3 for the quarter ending 2024-09-30 was $0.00.
  • VAXCYTE, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into level 3 for the quarter ending 2024-06-30 was $0.00.
  • VAXCYTE, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into level 3 for the quarter ending 2024-03-31 was $0.00.
  • VAXCYTE, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into level 3 for fiscal 2025 was $0.00.
  • VAXCYTE, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into level 3 for fiscal 2024 was $0.00.
  • VAXCYTE, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into level 3 for fiscal 2023 was $0.00.
  • VAXCYTE, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into level 3 for fiscal 2022 was $0.00.
Period endFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 3 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 6 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 9 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 12 month
2025-12-31$0.00
10-K · filed 2026-02-24
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$0.00
derived: sum of 2 quarters · filed 2026-02-24
$0.00
derived: sum of 3 quarters · filed 2026-02-24
$0.00
10-K · filed 2026-02-24
2024-09-30$0.00
10-Q · filed 2024-11-05
$0.00
derived: sum of 2 quarters · filed 2024-11-05
$0.00
10-Q · filed 2024-11-05
$0.00
derived: sum of 4 quarters · filed 2025-02-25
2024-06-30$0.00
10-Q · filed 2024-08-06
$0.00
10-Q · filed 2024-08-06
$0.00
derived: sum of 3 quarters · filed 2025-02-25
$0.00
derived: sum of 4 quarters · filed 2025-02-25
2024-03-31$0.00
10-Q · filed 2024-05-08
$0.00
derived: sum of 2 quarters · filed 2025-02-25
$0.00
derived: sum of 3 quarters · filed 2025-02-25
$0.00
derived: sum of 4 quarters · filed 2025-02-25
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25
$0.00
derived: sum of 2 quarters · filed 2025-02-25
$0.00
derived: sum of 3 quarters · filed 2025-02-25
$0.00
10-K · filed 2025-02-25
2023-09-30$0.00
10-Q · filed 2023-11-06
$0.00
derived: sum of 2 quarters · filed 2023-11-06
$0.00
10-Q · filed 2023-11-06
$0.00
derived: sum of 4 quarters · filed 2024-02-27
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
$0.00
10-Q · filed 2023-08-08
$0.00
derived: sum of 3 quarters · filed 2024-02-27
$0.00
derived: sum of 4 quarters · filed 2024-02-27
2023-03-31$0.00
10-Q · filed 2023-05-08
$0.00
derived: sum of 2 quarters · filed 2024-02-27
$0.00
derived: sum of 3 quarters · filed 2024-02-27
$0.00
derived: sum of 4 quarters · filed 2024-02-27
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27
$0.00
derived: sum of 2 quarters · filed 2024-02-27
$0.00
derived: sum of 3 quarters · filed 2024-02-27
$0.00
10-K · filed 2024-02-27
2022-09-30$0.00
10-Q · filed 2022-11-07
$0.00
derived: sum of 2 quarters · filed 2022-11-07
$0.00
10-Q · filed 2022-11-07
$0.00
derived: sum of 4 quarters · filed 2023-02-27
2022-06-30$0.00
10-Q · filed 2022-08-08
$0.00
10-Q · filed 2022-08-08
$0.00
derived: sum of 3 quarters · filed 2023-02-27
$0.00
derived: sum of 4 quarters · filed 2023-02-27
2022-03-31$0.00
10-Q · filed 2022-05-09
$0.00
derived: sum of 2 quarters · filed 2023-02-27
$0.00
derived: sum of 3 quarters · filed 2023-02-27
$0.00
derived: sum of 4 quarters · filed 2023-02-27
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27
$0.00
derived: sum of 2 quarters · filed 2023-02-27
$0.00
derived: sum of 3 quarters · filed 2023-02-27
$0.00
10-K · filed 2023-02-27
2021-09-30$0.00
10-Q · filed 2021-11-10
$0.00
derived: sum of 2 quarters · filed 2021-11-10
$0.00
10-Q · filed 2021-11-10
$0.00
derived: sum of 4 quarters · filed 2022-02-28
2021-06-30$0.00
10-Q · filed 2021-08-11
$0.00
10-Q · filed 2021-08-11
$0.00
derived: sum of 3 quarters · filed 2022-02-28
$0.00
derived: sum of 4 quarters · filed 2022-02-28
2021-03-31$0.00
10-Q · filed 2021-05-11
$0.00
derived: sum of 2 quarters · filed 2022-02-28
$0.00
derived: sum of 3 quarters · filed 2022-02-28
$0.00
derived: sum of 4 quarters · filed 2022-02-28
2020-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$0.00
derived: sum of 2 quarters · filed 2022-02-28
$0.00
derived: sum of 3 quarters · filed 2022-02-28
$0.00
10-K · filed 2022-02-28
2020-09-30$0.00
10-Q · filed 2020-11-12
$0.00
derived: sum of 2 quarters · filed 2020-11-12
$0.00
10-Q · filed 2020-11-12
2020-06-30$0.00
10-Q · filed 2020-08-12
$0.00
10-Q · filed 2020-08-12
2019-12-31$0.00
10-K · filed 2021-03-29
2018-12-31$0.00
10-K · filed 2021-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
REPLIGEN CORP (RGEN)United States$10.755B185.31
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
CRISPR Therapeutics AG (CRSP)$5.390B-11.68